Investigation finds mitochondrial replacement therapy marketed to older women despite scant evidence
A STAT News investigation reports that a reproductive technique developed to prevent mitochondrial disease inheritance is being sold internationally as a fertility treatment for advanced maternal age, with researchers quoted saying the evidence base is thin.
A STAT News investigation published on 2 November 2026 reports that mitochondrial replacement therapy (MRT) — a technique originally developed to reduce the risk of children inheriting serious mitochondrial diseases — is being marketed to women of advanced maternal age as a fertility treatment, despite limited published evidence that it improves live birth rates in that population.
MRT, sometimes called "three-parent IVF", involves transferring nuclear genetic material from one egg or embryo into an enucleated donor egg, with the aim of replacing dysfunctional maternal mitochondria. The technique carries regulatory approval in the United Kingdom specifically for preventing the transmission of mitochondrial disease; the STAT investigation describes women travelling internationally to clinics offering it off-label as a fertility intervention.
Scientists quoted in the investigation say women are being misled about the strength of the supporting evidence. A separate STAT reporter Q&A and reader callout published on the same date explore the ethics and personal experiences involved in seeking MRT as an infertility treatment.
The story raises questions relevant to genetic counsellors, reproductive specialists, and patient advocates about how emerging reproductive genetic technologies move from a narrowly defined regulatory indication into broader commercial use, and what informed consent looks like in that context. Mitochondrial genetics and inheritance patterns — including the maternal-only transmission of mitochondrial DNA — are directly implicated in the original clinical rationale for MRT.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Mitochondrial replacement therapy (MRT) is a specialist IVF technique originally developed to help women who carry certain inherited mitochondrial conditions — serious diseases passed down through the mother's egg — avoid passing those conditions to their children. In the UK it is regulated for that specific purpose.
A news investigation published by STAT News reports that some clinics around the world are now offering MRT to older women who are struggling to conceive, marketing it as a way to improve their chances of pregnancy. Researchers quoted in the investigation say there is currently little scientific evidence that it works for this purpose, and that some women seeking treatment may not have been given a full picture of what the evidence shows.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-11-02Women travel thousands of miles for a reproductive moonshot. Scientists say they've been misled
-
Stat News · 2026-11-02A STAT reporter on covering MRT as an experimental fertility treatment
-
Stat News · 2026-11-02Are you pursuing MRT as a treatment for infertility? Tell us about your experience